RECOMBINANT FACTOR-VIIA FOR INTRACRANIAL HEMORRHAGE IN A JEHOVAH-WITNESS WITH SEVERE HEMOPHILIA-A AND FACTOR-VIII INHIBITORS

A Jehovah's Witness with severe haemophilia A and a high titre, high r esponding inhibitor to both human and porcine factor VIII (FVIII) was treated with recombinant activated factor VII (rVIIa) during an episod e of intracranial bleeding. He recovered completely without any advers e effects or neurological sequelae. Treatment with rVIIa in this case was safe and effective. This therapeutic agent should be considered in haemophilia patients with inhibitors who refuse management with blood products on religious grounds and when recombinant factor VIII is not a cost-effective option.